Page 5 - தகவல்தொடர்புகள் பொது வாழ்க்கைத்தொழில்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(0) Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC) The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim s KRAS (Kirsten rat sarcoma) and TRAILR2 (TNF-related apoptosis-inducing ligand receptor 2) portfolios for the potential treatment of lung cancer, particularly non-small cell lung cancer.

United statesTimothy heffernanSarah soetbeerLinda ruckelBoehringer ingelheimClayton boldtNorbert krautTranslational research to advance therapeuticsUniversity of texas md anderson cancer centerDevelopment centerVirtual researchHead of oncology research in therapeutics discoveryCommunications public affairsBoehringer ingelheim corporate center gmbCancer centerTherapeutics discovery